Entecavir Therapy
Entecavir Therapy is a nucleos(t)ide analog therapy that specifically employs the guanosine analog entecavir to selectively inhibit hepatitis B virus reverse transcriptase, thereby suppressing viral replication in chronic hepatitis B infection.
634
Publications
35.3K
Citations
3.7K
Authors
1.1K
Institutions
Publications per year
2017–2026
208
Parents
634
1–5 of 634
3.7K
22
h-index
Bristol-Myers Squibb (United States), United States
26 publications · 6.7K citations
22
h-index
22
h-index
20
h-index
18
h-index
1–5 of 3.7K
1.1K
Bristol-Myers Squibb (United States)
New York, United States
41 h-index
267 publications
62.3K citations

Chang Gung University
Taoyuan City, Taiwan
27 h-index
231 publications
10.4K citations

University of Hong Kong
Pok Fu Lam, Hong Kong
24 h-index
176 publications
13K citations
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
23 h-index
226 publications
8K citations

Queen Mary Hospital
Hong Kong, China
21 h-index
136 publications
12.6K citations
Bristol-Myers Squibb (Germany)
Munich, Germany
21 h-index
84 publications
17.3K citations
Erasmus MC
Rotterdam, The Netherlands
21 h-index
99 publications
8.4K citations
Yonsei University
Seoul, South Korea
21 h-index
134 publications
8.6K citations
1–8 of 1.1K
37 publications · 7.4K citations
29
h-index
42 publications · 3K citations
28
h-index
42 publications · 1.3K citations
22
h-index
24 publications · 559 citations
18
h-index
29 publications · 855 citations
17
h-index
1–5